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A B S T R A C T
Aims: The aim of the present study was to evaluate the regulation of Aquaporin-2 (AQP2) water channel in the
kidney of one-kidney, one-clip rats (Goldblatt-1 model). In addition, some mechanisms that underlie the role of
AQP2 in the Goldblatt-1 model were evaluated.
Main methods: Sprague-Dawley rats were divided in three groups: control two-kidney, no clip (C, 2K-NC);
nephrectomized one-kidney, no clip (N, 1K-NC) and Goldblatt one-kidney, one-clip (G, 1K-1C). AQP2 expres-
sion (by westernblot, real time PCR, immunohistochemistry and immunofluorescence), vasopressin V2 receptor
expression (by real time PCR), cAMP concentration, NFkB and TonEBP (cytosol to nucleus ratio) were evaluated
in the renal medulla.
Key findings: AQP2 expression, V2 receptor expression and cAMP concentration were decreased in the renal
medulla of 1K-1C rats, NFkB translocation was favoured towards the nucleus suggesting its activation while
TonEBP translocation was not altered in this model of hypertension.
Significance: In this model of hypertension the decrease of AQP2 expression could be a mechanism that counter-
acts the high blood pressure promoting water excretion and this may be consequence of decreased vasopressin
sensitivity and/or the increased activity of NFkB at renomedullary collecting duct level. Given that renovascular
hypertension is among the most common causes of secondary hypertension, it is important to elucidate all the
relevant mechanisms involved in the generation or in the compensation of the hypertensive state in order to
improve the diagnoses and treatment of the patients.
1. Introduction
The kidney plays a central role in the regulation of salt and wa-
ter balance, contributing to the control of arterial blood pressure. This
regulation is achieved through the activity of both sodium and water
transporters. This work has a special focus on water transport mediated
by the aquaporins and in particular aquaporin-2 (AQP2). AQP2 plays
a central role in the final regulation of water reabsorption in the re-
nal collecting duct, being vasopressin (AVP) the main regulator of this
process [1]. AVP exerts its effects acting through three different recep-
tors: V1a, V1b (or V3) and V2 [2]. V1b receptors are present at cen-
tral nervous system level, being involved in cognitive functions in the
brain. Both V1a and V2 receptors are present in the kidney. V1a is as-
sociated with the vasa recta and is probably present in the intercalated
cells of the cortical collecting duct. V2 receptor, the unique AVP recep-
tor that signals through cAMP, has the key function of controlling fluid
homeostasis [3]. Binding of AVP to V2 receptors in the basolateral mem-
brane of principal cells in the collecting ducts stimulates adenylate cy-
clase producing cAMP, whose effects are mainly mediated by protein ki-
nase A (PKA) [4, 5].
AVP regulates water permeability in the renal collecting duct by
both short and long-term mechanisms. Short-term regulation occurs as
a result of the modulation of trafficking of AQP2-containing membrane
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vesicles to and from the apical plasma membrane and long-term regula-
tion occurs as a result of AQP2 expression regulation [6, 7].
Other proteins have been described as regulators of AQP2 expres-
sion, such as transcription factor tonicity responsive enhancer bind-
ing protein (TonEBP) [8] and the inflammatory mediator nuclear fac-
tor-kappaB (NFkB) [9]. TonEBP is a transcription factor activated un-
der hypertonic conditions to protect renal cells from hypertonic stress
stimulating the transcription of specific proteins [10]. Inflammation is a
key feature in the initiation, progression and clinical implication of sev-
eral cardiovascular diseases and the inflammatory response is essential
in the pathogenesis of hypertension [11–13].
In this pathology, focus has been made on sodium transport but
not on water transport, despite the importance of renal water handling
in this pathological condition. There are no conclusive studies about
the state of AQP2 during hypertension. However, some studies demon-
strated changes in AQP2 targeting and expression in different experi-
mental models of hypertension.
An increased expression and apical targeting of AQP2 in association
with enhanced activity of the AVP/cAMP pathway has been reported
in spontaneously hypertensive rats (SHR) [14–16]. On the other hand,
a decrease in AQP2 expression was described in a Goldblatt-2 model
of hypertension (two-kidney, one-clip; 2K-1C) [17, 18]. However, there
are no reports on the status of AQP2 in the Goldblatt-1 model of hyper-
tension (one-kidney, one-clip; 1K-1C). This renovascular model of hy-
pertension described by Goldblatt is appropriate for studying the role of
volume expansion in the development of hypertension [19, 20]. Since in
the model of 1K-1C there is no other kidney, there is no pressure diure-
sis and natriuresis, there is rapid salt and water retention and hyperten-
sion soon becomes volume dependent and plasma renin activity usually
remains normal after a short increase following the surgery [21, 22].
On these bases, the aim of the present study was to evaluate the reg-
ulation of AQP2 water channels in the kidney of one-kidney-one-clip
rats. In addition, some mechanisms that underlie the role of AQP2 in the
Goldblatt-1 model were evaluated.
2. Materials and methods
2.1. Animals and hypertension model
Male Sprague Dawley rats were purchased from Facultad de Cien-
cias Veterinarias -Universidad de Buenos Aires. Protocols were in com-
pliance with ARRIVE guidelines, were designed according to the Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals, and were approved by the Institutional Committee for Use
and Care of Laboratory Animals (CICUAL) from Facultad de Farmacia
y Bioquímica. Forty-five-day-old rats weighing 150g were anesthetized
with Ketamine/Xylazine (50–10, mg/Kg of body weight), the left kid-
ney was exposed and a 0.25mm gap silver clip was placed around the
renal artery. For right nephrectomy, two ligatures were made around
the renal vascular pedicle and the ureter. The kidney was then removed
without the adrenal gland (Goldblatt rats). In another group of rats only
the right kidney was extracted (nephrectomized rats) and a third group
was subjected to a sham surgery procedure, with the exception of the
artery clip and the nephrectomy (Control rats). All rats received 0.1ml
(40,000IU) of amoxicillin at the end of the surgery.
Therefore we worked with three groups: control two-kidney-no clip
(C, 2K-NC, n=12); nephrectomized one-kidney-no clip (N, 1K-NC
n=12) and Goldblatt hypertensive group one-kidney-one-clip (G,
1K-1C, n=15), which were studied four weeks after surgery.
2.2. Determination of systolic blood pressure
Systolic BP was recorded weekly in conscious rats by tail plethys-
mography (ADInstruments PowerLab 8/30 and NIBP Controller
ML125).
2.3. Determinations in the 24-h metabolic cage studies
Animals were acclimatized to metabolic cages for 2days before 24h
urine collection. Urine samples were analyzed for total protein concen-
tration (Proti U/LCR Kit; Wiener Lab., Rosario, Argentina) and urine os-
molality (OSMETTE, Precision Systems Inc., MA, USA). Urine volume
was measured gravimetrically. Kinetic determinations of serum and uri-
nary creatinine concentration were evaluated using a kit provided by
Wiener. Urinary sodium was measured using an ion analyzer (Tecnolab;
Mod. T-412, Argentina).
Blood collection was performed with the rats under urethane anes-
thesia (1g/Kg via i.p) by cardiac puncture; animals were killed by
exsanguination, then both kidneys or the remaining kidney were imme-
diately removed and weighed.
2.4. Tissue processing for Western blot analysis in medulla homogenates
Immediately after the animals were sacrificed, their kidneys were
isolated and the renal medulla was dissected and homogenized in an ap-
propriate homogenization buffer (250mmol/l sucrose, 1mmol/l EDTA,
0.1mmol/l PMSF and 10mmol/l Tris-ClH), pH7.6. Large tissue de-
bris and nuclear fragments were removed by a low-speed spin (1000g,
10min, 4°C). Protein concentration was measured using BCA TM Pro-
tein Assay Kit (Pierce, Rockford, IL, USA).
2.5. Western blot for AQP2
Immunoblotting analysis was used to identify AQP2. AQP2 antibody
(rabbit anti-rat AQP2; Santa Cruz Biotechnology, Inc., CA, USA) was fol-
lowed by a donkey anti-rabbit IgG (HRP) secondary antibody (Abcam
Inc., Cambridge, MA, USA) and revealed using Bio-Lumina kit (Kalium
Technologies; Buenos Aires, Argentina). Beta-tubulin was used as load-
ing control (Abcam). AQP2 antibody recognizes at least two bands of 29
and 35–40kDa corresponding to unglycosylated and glycosylated AQP2,
respectively.
The relative protein levels were analyzed with Gel Pro Analyzer 3.1
for Windows and the ratio of AQP2 to beta-tubulin was calculated.
2.6. Tissue processing for Western blot analysis in cytosolic fraction and
purified nuclei
After homogenization of the renal medulla, the homogenate was cen-
trifuged for 10min at 800×g to obtain the nuclear fraction in the pel-
let and the cytosolic fraction in the supernatant. The pellet was washed
with homogenization buffer and suspended in a solution of 2.4M su-
crose followed by a centrifugation at 50000×g for 1h to obtain the pu-
rified nuclei in the pellet.
2.7. Western blots for NFkB and TonEBP
Immunoblotting analysis was used to identify NFkB or TonEBP in
the cytosolic fraction and in purified nuclei. The appropriate primary
antibody (mouse anti-rat NFkB, Santa Cruz Biotechnology, or rabbit
anti-rat TonEBP; Santa Cruz Biotechnology) was followed by a sec-
ondary antibody (Horse anti mouse HRP, GE Healthcare, UK or don-
key anti-rabbit IgG HRP Abcam) and revealed as described above. NFkB
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antibody recognizes a 65-kDa band corresponding to p65 subunit and
TonEBP antibody recognizes a 170-KDa band.
Beta-tubulin was used as loading control for the cytosolic fraction
and Lamina (Mouse anti rat Millipore MA, USA) was used as loading
control for the purified nuclei. The relative protein levels were analyzed
with Gel Pro Analyzer 3.1 for Windows and the ratio of cytosolic to nu-
clei expression was used as an indicator of transcription factor activa-
tion.
2.8. Real-time PCR for AQP2 and V2 receptor
Total RNA was isolated using the SV total RNA Isolation System
(Promega) and reverse transcribed to cDNA using a high capacity re-
verse transcription kit (A&B, MA, USA). For real-time detection of AQP2
and V2 transcripts and the reference gene (GAPDH), MezclaReal (Bio-
dynamics, Buenos Aires, Argentina) and specific primers were used [23,
24]. The normalized gene expression method (2⁠–∆∆CT) for the relative
quantification of gene expression was used [25].
2.9. cAMP measurements
cAMP was measured in the renal medulla. Approximately 100mg of
renal medulla was homogenized in ice-cold absolute ethanol and cen-
trifuged for 15min at 1200g. The supernatant was dried, and the re-
maining residue was suspended for cAMP determination by competition
of [3H]-cAMP for PKA [26]. Results were expressed as pmoles/mg of
protein.
2.10. Immunohistochemistry for AQP2
Five micrometer slices were incubated with primary rabbit poly-
clonal antibody to AQP2 (Abcam) and a secondary biotinylated don-
key anti rabbit (Jackson ImmunoResearch, West Grove, PA, USA), fol-
lowed by the streptavidin-biotin-peroxidase reaction (Dako Cytoma-
tion, Glostrup, Denmark) visualized by exposure to diaminobenzidine
(DAB)-H⁠2O⁠2. Endogenous peroxidase activity was quenched with hydro-
gen peroxide to prevent unspecific staining. Tissue sections were coun-
terstained with hematoxylin.
2.11. Immunofluorescence for AQP2
Kidneys were fixed with 4% paraformaldehyde, pH7.4, cryopro-
tected in 5% and 25% sucrose/PBS, pH7.4 and frozen at −70°C. Then
the kidneys were cut in 5μm slices. Kidney sections were incubated with
a primary rabbit polyclonal antibody to AQP2 (Abcam) followed by a
secondary FITC labeled donkey anti rabbit antibody (Alexa fluor 488,
goat anti rabbit Ig G; Invitrogen) and mounted with Vectashield Mount-
ing Medium (Vector Laboratories, Burlingame, CA, USA).
2.12. Image capture and analysis
All determinations were performed blindly and under similar light,
gain and offset conditions by the same operator.
Images from immunohistochemical sections were captured using
a Nikon Alphaphot-2 YS2 light microscope (Nikon Instrument Group,
Melville, NY), coupled to a Sony color video camera digital (Model No.
SSC-DC50A).
Images from immunofluorescence were examined by wide-field mi-
croscopy with an epifluorescence Nikon Eclipse Ti microscope. Images
were taken with the acquisition freeware Micrometric SE premium.
2.13. Statistics
One-way ANOVA with Bonferroni's post-test for multiple compar-
isons was performed using Graph Pad Prism version 5.0 for Windows.
3. Results
3.1. Characterization of the animal model
Data for renal functional parameters and systolic BP 4weeks after
the surgical procedure are shown in Table 1.
Systolic BP was significantly higher in 1K-1C group compared to
control and 1K-NC groups (p<0.001). Kidney weight/100g b.w. in-
creased in both 1K-NC (p<0.01) and 1K-1C (p<0.001) groups com-
pared to the control group meanwhile there were no differences in body
weight between the three groups. Kidney size increases in a number
of physiological and pathological situations, including uninephrectomy.
Renal mass increases after nephrectomy mainly in the cortex, particu-
larly in the proximal convoluted tubules, and appears to be of a hyper-
trophic, rather than hyperplastic nature and is mediated by a cell cy-
cle-dependent mechanism [27].
Urinary volume significantly increased in 1K-1C group compared to
control group (p<0.05), meanwhile only had a tendency to increase in
1K-NC group. Urinary osmolality decreased in 1K-1C group compared
to both 1K-NC and the control group (p<0.05).
Table 1
Systolic blood pressure and renal functional parameters.
2K-NC 1K-NC 1K-1C
Systolic arterial pressure (mmHg) 124.7±0.9 (n=7) 123.6±1.0 (n=7) 185.0±15.9⁠⁎⁎⁎,### (n=7)
Kidney weight (g) 1.46±0.04 (n=12) 2.13±0.10⁠⁎⁎⁎ (n=12) 2.26±0.13⁠⁎⁎⁎ (n=15)
Body weight (g) 348.1±15.8 (n=11) 331.0±22.0 (n=11) 320.6±12.6 (n=14)
Kidney weight/100gb.w. (g/100g) 0.35±0.03 (n=11) 0.59±0.02⁠⁎⁎ (n=11) 0.67±0.05⁠⁎⁎⁎ (n=14)
Urinary volume (ml/24h) 8.8±1.1 (n=6) 13.3±1.8 (n=10) 18.1±2.5⁠⁎ (n=10)
Urinary Osmolality (mOSm/L) 1870±210 (n=6) 1910±169 (n=6) 964±245⁠⁎,# (n=7)
Urinary sodium (meq/24h) 2.98±0.95 (n=6) 3.44±0.88 (n=6) 2.88±0.47 (n=7)
Proteinuria (mg/24) h/100g) 3.12±0.60 (n=6) 4.41±0.42 (n=6) 5.67±0.72⁠⁎ (n=6)
Creatinine clearance (ml/min/100g) 0.37±0.07 (n=6) 0.32±0.02 (n=6) 0.37±0.10 (n=6)
2K-NC: control group; 1K-NC: one kidney-no clip; 1K-1C: one kidney-1 clip hypertensive group. One-way ANOVA followed by Bonferroni's test for multiple comparisons.
⁎ p<0.05 vs 2K-NC.
⁎⁎ p<0.01 vs 2K-NC.
⁎⁎⁎ p<0.001 vs. 2K-NC.
# p<0.05 vs. 1K-NC.
### p<0.001 vs. 1K-NC. Data are mean±SEM.
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Proteinuria significantly increased in 1K-1C group when compared
to control group (p<0.05). There were no significant differences in cre-
atinine clearance and urinary sodium excretion among the three groups.
Aquaporin-2 expression is decreased in the renal medulla of the hy-
pertensive 1K-1C rats.
Fig. 1 shows that both AQP2 protein and mRNA expression were de-
creased in the renal medulla of 1K-1C rats compared to both 1K-NC
and control groups (p<0.05). We evaluated AQP2 expression both at
protein and mRNA levels because uncoupled expression between AQP2
mRNA and protein has been described under certain conditions [28].
The results of AQP2 Western blot were corroborated by immunohis-
tochemistry and immunofluorescence (Fig. 2). The images obtained by
immunofluorescence show AQP2 labeling both in the cytosol and in the
apical membranes of the principal cells for the three groups, there were
no net changes in AQP2 translocation in none of the studied groups.
3.2. V2 receptor expression and cAMP production are decreased in the
renal medulla of hypertensive 1K-1C rats
V2 receptor mRNA expression decreased in the renal medulla of
1K-1C rats compared to both 1K-NC and control groups (p<0.01), as
can be shown in Fig. 3A.
Fig. 3B shows that cAMP production decreased in the renal medulla
of 1K-1C rats compared to both 1K-NC and control groups (p<0.01).
Fig. 1. Aquaporin-2 expression in homogenates of renal medullaA1. Representative Western Blot analysis of AQP2 (28 and 35–40kDa) and tubulin (50kDa) in homogenates of renal
medulla. A2. AQP2 protein expression indicated as AQP2/tubulin ratio fold change from 2k-NC control rats. B. AQP2 mRNA levels are expressed as relative values from 2K-NC control
rats. The following formula was applied: ∆∆CT=(CTAQP2-CTGAPDH) experimental – (CTAQP2-CT GAPDH) 2K-NC control rats.2K-NC: control group; 1K-NC: one kidney, no clip; 1K-1C:
one kidney, 1 clip hypertensive group. One-way ANOVA followed by Bonferroni's test for multiple comparisons. *p<0.05 vs 2K-NC, #p<0.05 vs 1K-NC rats. Data are mean±SEM
(n=6).
Fig. 2. Aquaporin-2 protein expression in histological sectionsA–C: Representative images of immunohistochemical staining for AQP2. All images are in the same magnification: 400×.
Each arrow shows a representative collecting duct principal cell. D–F: Representative images of Immunofluorescence staining for AQP2. All images are in the same magnification: 600×.
Each arrow shows apical staining for AQP2.2K-NC: control group; 1K-NC: one kidney, no clip; 1K-1C: one kidney, 1 clip hypertensive group; (n=3).
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Fig. 3. V2 receptor expression and cAMP concentration in renal medullaA: V2 receptor mRNA levels are expressed as relative values from 2K-NC control rats. The following formula
was applied: ∆∆CT=(CTV2R-CTGAPDH) experimental – (CT V2R-CT GAPDH) 2K-NC control rats. B: cAMP concentration assessed by competition of [3H]-cAMP for PKA.2K-NC: control
group; 1K-NC: one kidney, no clip; 1K-1C: one kidney, 1 clip hypertensive group. One-way ANOVA followed by Bonferroni's test for multiple comparisons. **p<0.01 vs. 2K-NC, ##
p<0.01 vs. 1K-NC rats. Data are mean±SEM (n=4).
3.3. NFkB is activated in hypertensive 1K-1C rats
Fig. 4A shows that cytosolic/nuclear ratio of NFkB expression de-
creased in hypertensive 1K-1C rats, due to the increase in NFkB nuclear
localization. NFkB was shown to negatively regulate AQP2 expression,
so this activation of NFkB could be contributing to AQP2 downregula-
tion.
3.4. TonEBP translocation is not altered in the renal medulla of
hypertensive 1K-1C rats
Fig. 4B shows that cytosolic/nuclear ratio of TonEBP expression did
not change in 1K-1C animals when compared to control group or to the
nephrectomized group, indicating that Ton EBP is not activated in this
model of hypertension.
4. Discussion
In this work we show that AQP2 expression is altered in 1K-1C hy-
pertension with a decrease in both protein expression and mRNA levels.
The decrease in AQP2 expression results in an altered urinary concentra-
tion that leads to an increased urinary volume and a decreased urinary
osmolality in 1K-1C hypertensive group. The fact that AVP pathway is
also altered may explain, at least in part, the diminished AQP2 expres-
sion and the increased diuresis found in this hypertension model. These
results are in accordance with those reported by Lee et al., who also
showed a reduced expression of AQP2 without changes in its translo-
cation and a diminished cAMP production in the clipped kidney from
2K-1C rats, another model of Goldblatt renovascular hypertension [17].
Contrary to results mentioned above, it was reported that the
medullary expression and apical targeting of AQP2 and adenylate cy-
clase activity are increased in the kidney of SHR, contributing to the
pathogenesis of hypertension [14, 16]. Similarly, in the kidney of
Fig. 4. NFKb and Ton EBP cytosolic/nuclear ratio in renal medullaA1: Representative western blot analysis of NFkB p65 (65kDa) in cytosolic fraction and purified nuclei of renal medulla.
A2. NFkB activation indicated as cytosolic/nuclear ratio fold change from 2K-NC control rats. B1 Representative western blot analysis of Ton EBP (170kDa) in cytosolic fraction and
purified nuclei of renal medulla. B2. TonEBP cytosolic/nuclear ratio fold change from 2K-NC control rats.2K-NC: control group; 1K-NC: one kidney, no clip; 1K-1C: one kidney, 1 clip
hypertensive group. One-way ANOVA followed by Bonferroni's test for multiple comparisons. *p<0.05 vs. 2K-NC. Data are mean±SEM (n=3).
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DOCA-salt hypertensive rats, a model where hypertension maintenance
has been attributed to increased AVP, cAMP and AQP2 expression and
shuttling are increased suggesting that they are causally related with the
development of hypertension [29].
In this work we show a decrease in V2 receptor expression and cAMP
reduction in the renal medulla of 1K-1C rats. AVP plays an important
role in the regulation of BP by means of V1 and V2 receptors; however
the regulation of the expression of these receptors in hypertension is not
completely understood. Burrell et al. demonstrated that in SHR, increase
of plasma AVP and activation of renal V1a receptor occurs during devel-
oping hypertension, with downregulation when hypertension is estab-
lished [24]. Contrary to our results, they did not observe changes in V2
receptor expression, but the study was conducted in a different model
of hypertension [17, 30]. Some authors have shown that plasma AVP
is elevated in rats with 1K-1C Goldblatt hypertension [31, 32]. Share
et al. pointed out that AVP may contribute to 1K-1C hypertension by
virtue of its antidiuretic action, allowing the expansion of blood volume
that apparently is necessary for the chronic stage of the hypertensive
state [33]. Lariviere et al. showed that together with an increased con-
centration of AVP in plasma, the number of vascular AVP-binding sites
is decreased in 1K-1C hypertensive rats [32]. So it is possible that in-
creased AVP levels leads to a decrease in renal medullary V2 receptor
expression as a compensatory mechanism, diminishing AVP sensitivity
and consequently decreasing cAMP levels and AQP2 expression in order
to counteract the volume expansion.
On the other hand, the reduction in cAMP production and conse-
quently AQP2 decrease may be consequence of the ischemic condition
of the clipped kidney [17, 34], which in turn promotes oxidative stress.
It is known that an increase in oxidative stress plays a role in renovas-
cular hypertension [35, 36] and that the interaction between reactive
oxygen species (ROS) and NO reduces its bioavailability [37] In a pre-
vious work we demonstrated that AQP2 is down-regulated in the renal
medulla of rats made hypertensive by chronic inhibition of nitric oxide
synthase [38] and later we provided evidence that NO has a role in the
control of AQP2 expression [39]. Besides the decrease in NO bioavail-
ability, the interaction of ROS with NO promotes the increase in pro-ox-
idant peroxynitrite. The combination of diminished NO bioavailability
and increased peroxynitrite impairs intrarenal vascular, glomerular and
tubular function [37].
TonEBP, a protein known to regulate AQP2 expression by enhancing
its gene transcription independently of AVP action, is not activated in
this model of hypertension, since this is a volume-dependent hyperten-
sion model and TonEBP is activated in hypertonic environments [40].
As expected, NFkB is activated in this model of hypertension which
courses with the development of pro-inflammatory mechanisms. It was
already shown that inflammatory processes contribute to the increased
arterial pressure in human essential arterial hypertension and in dif-
ferent animal models of experimental hypertension [41]. Besides, it is
known that NFkB activation is important for the downregulation of
AQP2 channel and vasopressin V2 receptor expression during sepsis
[42] and other inflammatory diseases [9]. Hasler et al. identified NFkB
as a negative acting transcription factor that physiologically controls
AQP2 transcription and may antagonize both CREB and TonEBP stimu-
latory effects. In that article the authors said that the strong activation
of NFkB observed in renal inflammatory diseases is most likely to ac-
count for the observed decrease of AQP2 expression and accompanies
urinary concentration defects [9]. The analysis of AQP2 promoter re-
vealed two putative kB binding elements. NFkB stimulates or represses
target gene transcription depending on the nature of the bound NFkB
homo- or heterodimer and on bound NFkB cofactors [9]. The differen-
tial dimerization between NFkB family members allows for cell-specific
transcriptional modulation of target genes in response to a great num-
ber of stimuli [9]. Hasler et al. showed that LPS treatment of cultured
mouse CD principal cells or rat kidney slices decreased AQP2 expres-
sion, being this effect mediated by decreased p65 and increased p50 and
p52 binding to kB elements of AQP2 promoter [9]. This result is oppo-
site to our finding because we found that in 1K-1C hypertensive Gold-
blatt model AQP2 expression decreases as a consequence of increased
nuclear localization of p65. However, in accordance to us Lin et al.
found that knockdown of NF-kBp65 or NF-kBp65 inhibition by pyrroli-
dine dithiocarbamate (PDTC) enhanced AQP2 expression in IMCD cells
exposed to TNF-α [43].
5. Conclusions
Our results allow us to conclude that, in Goldblatt-1 hypertensive
model, the decrease of AQP2 could be counterbalancing the enhance-
ment in BP by increasing water excretion as a consequence of the de-
crease in vasopressin sensitivity, although this needs further investiga-
tion. On the other hand, we cannot discard activation of NFkB as a
mechanism contributing to AQP2 downregulation although it would be
hard to conceive inflammation as a compensatory mechanism for hyper-
tension since it is actually one of the initiating factors.
Hypertension is one of the leading causes of morbidity and mortal-
ity and increases every year. Renovascular hypertension is among the
most common causes of secondary hypertension [37]. Therefore, it is
very important to elucidate all the relevant mechanisms involved in the
generation or in the compensation of the hypertensive state in order to
improve the diagnoses and treatment of the patients.
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